TY  - JOUR

T1  - Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy.

JO  - Journal of Clinical Oncology

UR  - http://dx.doi.org/10.1200/jco.2022.40.28_suppl.293

PY  - 2022/10/01

AU  - Craig Z

AU  - Swain J

AU  - Sharma R

AU  - Faluyi OO

AU  - Wadsley J

AU  - Morgan C

AU  - Wall LR

AU  - Chau I

AU  - Reed NS

AU  - Sarker D

AU  - Margetts J et al

ED  - 

DO  - DOI: 10.1200/jco.2022.40.28_suppl.293

PB  - American Society of Clinical Oncology (ASCO)

VL  - 40

IS  - 28_suppl

SP  - 293

EP  - 293

Y2  - 2025/05/19

ER  -